VVOS - Vivos Therapeutics reports results of Class 1 DNA appliance in obstructive sleep apnea

Vivos Therapeutics ([[VVOS]] -0.4%) announces results from a national study to assess patients’ airway function and obstructive sleep apnea ((OSA)) symptoms after undergoing the Vivos treatment. In the study, 28% of the 74 adult patients treated with the Company’s FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms, which is defined as patients having an Apnea Hypopnea Index ((AHI)) score of less than five post-treatment. Patients who experienced little to no OSA symptoms may no longer require CPAP, neuro-stimulation, or other lifetime interventions. 82% of the patients showed some improvement in AHI scores, with 64% improving by at least one full category, such as moderate to mild OSA.In 15% of patients, AHI scores worsened, and in 4% there was no change.Average treatment time with Class 1 DNA appliance was just 14 months.This real world patient data has been submitted to the FDA to be used as

For further details see:

Vivos Therapeutics reports results of Class 1 DNA appliance in obstructive sleep apnea